Lonza appoints Pierre-Alain Ruffieux as new Chief Executive Officer

BASEL, SWITZERLAND: The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals. Albert Baehny, Chairman of the Board said: “The Board is delighted to have appointed someone…

Glycotest receives $3mn second tranche of $10mn Series A financing

NEW YORK: Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis, has received the second $3 million tranche of the $10 million Series A financing round from Shanghai Fosun Pharmaceutical Co., Ltd.  The focus of this strategic investment is the advancement of the HCC Panel toward…